CRP and congenital rubella syndrome: Tocilizumab’s long, half-life (12, 13)supports this interpretation, as does the observation that IL-6 levels were only mildly elevated during CRS (16.3 pg/mL vs. baseline 9.5 pg/mL) despite marked systemic inflammation (CRP 4.89 mg/dL).